logo
welcome
Reuters

Reuters

Eli Lilly raises annual forecasts as weight-loss drug quarterly sales cross $1 billion

Reuters
Summary
Nutrition label

80% Informative

Shares of Eli Lilly rose more than 9% in premarket trading, with sales of its weight-loss drug, Zepbound , crossing $1 billion for the first time in a quarter .

The strong sales number for the drug comes a day after Danish rival Novo Nordisk reported a rare miss on quarterly sales of Wegovy .

VR Score

90

Informative language

95

Neutral language

79

Article tone

formal

Language

English

Language complexity

41

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links